公开(公告)号：US4324894A

公开(公告)日：1982-04-13

申请号：US138843

申请日：1980-04-10

申请人： Pal Benko ,  Andras Gelleri ,  Gyorgy Hajos ,  Andras Messmer ,  Laszlo Pallos ,  Lujza Petocz ,  Ibolya Kosoczky ,  Katalin Grasser ,  Peter Gorog ,  Eniko Szirt nee Kiszelly

发明人： Pal Benko ,  Andras Gelleri ,  Gyorgy Hajos ,  Andras Messmer ,  Laszlo Pallos ,  Lujza Petocz ,  Ibolya Kosoczky ,  Katalin Grasser ,  Peter Gorog ,  Eniko Szirt nee Kiszelly

IPC分类号： A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/495 ,  A61P25/00 ,  A61P25/04 ,  C07D217/22 ,  C07D217/24 ,  C07D401/12 ,  C07D413/04 ,  C07D403/14

CPC分类号： C07D217/22 ,  C07D217/24

摘要： Novel aminoisoquinoline derivatives of the general formula (I) ##STR1## wherein R.sub.1 represents a hydrogen atom or a C.sub.1-4 alkyl group,R.sub.2 represents a hydrogen atom,R.sub.3 represents a hydrogen atom,R.sub.4 represents a morpholinyl group or a piperazinyl group substituted with a pyridyl group, andpharmaceutically acceptable acid addition salts and quaternary derivatives thereof have been prepared. The novel compounds exert narcosis potentiating effects.

摘要翻译： 通式（I）的新型氨基异喹啉衍生物其中R 1表示氢原子或C 1-4烷基，R 2表示氢原子，R 3表示氢原子，R 4表示吗啉基或哌嗪基 已经制备了被吡啶基取代的基团，以及其药学上可接受的酸加成盐和其季衍生物。 新型化合物发挥麻醉加强作用。

公开(公告)号：US4871846A

公开(公告)日：1989-10-03

申请号：US43600

申请日：1987-04-28

申请人： Sandor Batori ,  Gyorgy Hajos ,  Andras Messmer ,  Pal Benko ,  Laszlo Pallos ,  Lujza Petocz ,  Katalin Grasser ,  Ibolya Kosoczky ,  Eniko Szirt nee Kiszelly

发明人： Sandor Batori ,  Gyorgy Hajos ,  Andras Messmer ,  Pal Benko ,  Laszlo Pallos ,  Lujza Petocz ,  Katalin Grasser ,  Ibolya Kosoczky ,  Eniko Szirt nee Kiszelly

IPC分类号： C07D215/12 ,  C07D215/58 ,  C07D217/16 ,  C07D217/18 ,  C07D471/04

CPC分类号： C07D471/04 ,  C07D215/58 ,  C07D217/18

摘要： A process for the preparation of condensed as-triazinium derivatives of the formula I ##STR1## and isomers thereof, wherein R.sub.1 inter alia is an alkyl group, R.sub.2 inter alia is hydrogen or an alkyl group and R.sub.3 is hydrogen and where Z is a group of the formula a or b ##STR2## which comprises reacting a compound of the formula II ##STR3## where Y is a group of the formula c or d ##STR4## with a compound of the formula IIaNH.sub.2 --CO--R.sub.2 (IIa)in the presence of a dehydrating agent. The advantage of the process is that it consists of fewer reaction steps and provides higher yields than the known methods. The compounds of formula I are pharmaceutically active known derivatives.

摘要翻译： 一种制备式I（I）的缩合的三嗪鎓衍生物及其异构体的方法，其中R1特别是烷基，R 2特别是氢或烷基，R 3是氢，并且其中Z 是式a或b的基团（a）（b），其包括使式II的化合物（II）其中Y是式c的基团或d （c）在脱水剂存在下，用式IIa NH 2 -CO-R 2（IIa）化合物与（d）化合物反应。 该方法的优点在于其由较少的反应步骤组成，并提供比已知方法更高的产率。 式I的化合物是药学活性的已知衍生物。

公开(公告)号：US4419355A

公开(公告)日：1983-12-06

申请号：US283971

申请日：1981-07-16

申请人： Ibolya Kosoczky ,  Eva Toncsev, nee Ravasz ,  Pal Benko ,  Laszlo Pallos ,  Lujza Petocz ,  Sandor Batori ,  Gyorgy Hajos ,  Andras Messmer ,  Katalin Grasser

发明人： Ibolya Kosoczky ,  Eva Toncsev, nee Ravasz ,  Pal Benko ,  Laszlo Pallos ,  Lujza Petocz ,  Sandor Batori ,  Gyorgy Hajos ,  Andras Messmer ,  Katalin Grasser

IPC分类号： C07D471/04 ,  A61K31/53 ,  A61P25/24 ,  A61P25/26 ,  C07D253/10 ,  C07D487/04 ,  C07D253/08

CPC分类号： C07D487/04

摘要： The invention relates to new condensed as-triazine derivatives of the general formula (I) ##STR1## wherein Z represents a buta-1,3-dienyl group or a group of the formula (a), (b), (c) or (d) ##STR2## R.sub.1 denotes a C.sub.1-10 alkyl group, an oxo group or a C.sub.6-10 aryl or C.sub.6-10 aryl-(C.sub.1-3 alkyl) group optionally substituted by one or more identical or different substituents selected from the group consisting of amino, nitro, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy and halogen,R.sub.2 stands for hydrogen, C.sub.1-10 alkyl or amino,R.sub.3 represents hydrogen, C.sub.1-10 alkyl or C.sub.6-10 aryl or C.sub.6-10 aryl-(C.sub.1-3 alkyl) optionally substituted by one or more identical or different substituents selected from the group consisting of nitro, amino, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy and halogen,X.sup.- denotes an anion, andn is 0 or 1,with the proviso that if n is O, R.sub.1 is other than an oxo group and R.sub.1 ' and R.sub.2 ' form together a double bond, and with the further provisos that if n is 1, R.sub.1 represents an oxo group and the symbols R.sub.1 ' and R.sub.2 ' are not present, and if Z is a buta-1,3-dienyl group and R.sub.1 denotes an oxo group, R.sub.3 is other than unsubstituted phenyl.The new compounds of the general formula (I) can be prepared by cyclizing the compounds of the general formula (II) or (V), wherein R.sub.1, Z, R.sub.3 and X.sup.- have the above defined meanings, R.sub.4 is a leaving group and R.sub.7 represents hydrogen or C.sub.1-10 alkyl.The new compounds of the general formula (I) possess a valuable antidepressant effect and can advantageously be used in the therapy.

摘要翻译： 本发明涉及通式（I）的新的缩合的三嗪衍生物，其中Z代表丁-1,3-二烯基或式（a），（b），（ c）或（d）R1表示任选被一个或多个相同的C 1-6烷基，氧代基或C 6-10芳基或C 6-10芳基 - （C 1-3烷基） 或选自氨基，硝基，C 1-6烷基，C 1-6烷氧基，羟基和卤素的不同取代基，R 2代表氢，C 1-10烷基或氨基，R 3表示氢，C 1-10烷基或C 6- 芳基或任选被一个或多个相同或不同的选自硝基，氨基，C 1-6烷基，C 1-6烷氧基，羟基和卤素的取代基取代的芳基或C 6-10芳基 - （C 1-3烷基） 表示阴离子，n为0或1，条件是如果n为O，则R1不是氧代基，R1'和R2'一起形成双键，另外条件是，如果n为1， R1代表氧代基团， mbols R1'和R2'不存在，并且如果Z是丁-1,3-二烯基并且R 1表示氧代基，则R 3不是未取代的苯基。 通式（I）的新化合物可以通过使通式（II）或（V）的化合物环化来制备，其中R1，Z，R3和X具有上述定义，R4是离去基团， R 7表示氢或C 1-10烷基。 通式（I）的新化合物具有有价值的抗抑郁作用，可有利地用于治疗。

公开(公告)号：US4395413A

公开(公告)日：1983-07-26

申请号：US162674

申请日：1980-06-24

申请人： Zoltan Budai ,  Aranka Lay nee Konya ,  Tibor Mezei ,  Lujza Petocz ,  Katalin Grasser ,  Ibolya Kosoczky ,  Eniko Szirt nee Kiszelly ,  Peter Gorog

发明人： Zoltan Budai ,  Aranka Lay nee Konya ,  Tibor Mezei ,  Lujza Petocz ,  Katalin Grasser ,  Ibolya Kosoczky ,  Eniko Szirt nee Kiszelly ,  Peter Gorog

IPC分类号： A61K31/15 ,  A61K31/495 ,  A61P25/04 ,  C07C67/00 ,  C07C239/00 ,  C07C249/10 ,  C07C251/58 ,  C07D295/02 ,  C07D295/088 ,  C07D295/08

CPC分类号： C07D295/088 ,  Y10S514/926 ,  Y10S514/927

摘要： The invention relates to novel oxime ethers of the general formula /I/ and acid addition salts and quaternary ammonium derivatives thereof, ##STR1## wherein A represents a C.sub.2-6 straight or branched alkylene chain,R and R.sup.1 each represent a C.sub.1-6 alkyl group or they form together with the adjacent nitrogen atom a heterocyclic ring containing 4 to 7 carbon atoms and optionally a further hetero atom, i.e. an oxygen, sulfur or nitrogen atom, and said ring may be optionally substituted by a C.sub.1-3 alkyl, phenyl or benzyl group,R.sup.2 and R.sup.3 each denote a hydrogen atom or together form a valency bond,R.sup.4 denotes a C.sub.1-10 alkyl or C.sub.2-10 alkenyl group, andn denotes an integer from 3 to 7.The compounds of the general formula /I/ are prepared according to the invention by reacting a cycloalkane derivative of the general formula /II/ ##STR2## wherein R.sup.2, R.sup.3, R.sup.4 and n have the same meaning as above, whereasY denotes an oxygen or sulphur atom or a .dbd.N--OH group with an aminoalkyl derivative of the general formula /III/ ##STR3## wherein R, R.sup.1 and A have the same meaning as stated above andZ means a halogen atom or a H.sub.2 N--O-- group or a salt thereof in the presence of a basic condensing agent.The new compounds of the general formula /I/ possess valuable nicotine-lethality inhibiting, local anaesthetic, analgesic effects, which are, in case of certain compounds, complemented by anti-hypertensive, maximum electroshock and tetracorspasm inhibiting, ulcus inhibiting and motility inhibiting effects, and can be applied to advantage in the therapy.

摘要翻译： 本发明涉及通式I I的新型肟醚及其酸加成盐和季铵衍生物，其中A表示C2-6直链或支链亚烷基链，R和R1各自表示C1 -6烷基，或者它们与相邻的氮原子一起与含有4至7个碳原子的杂环和任选的另外的杂原子（即氧，硫或氮原子）一起形成，并且所述环可以任选地被C 1-3 烷基，苯基或苄基，R2和R3各自表示氢原子或一起形成价键，R4表示C1-10烷基或C2-10烯基，n表示3至7的整数。 根据本发明通过使通式/ II / IMAGE / II /的环烷烃衍生物与其中R2，R3，R4和n具有与上述相同的含义反应制备通式/ I / I，而Y表示氧或 硫原子或a =具有氨基烷基衍生物的N-OH基团 通式/ III / / III /其中R，R 1和A具有与上述相同的含义，Z表示在碱性缩合剂存在下的卤素原子或H 2 N-O-基或其盐。 新型化合物/ I /具有有价值的尼古丁杀伤力抑制，局部麻醉，止痛作用，在某些化合物的情况下，补充有抗高血压，最大电休克和四疣抑制作用，抑制溃疡和运动抑制作用 ，并且可以在治疗中有利地应用。

公开(公告)号：US4697013A

公开(公告)日：1987-09-29

申请号：US652613

申请日：1984-09-20

申请人： Andras Messmer ,  Sandor Batori ,  Gyorgy Hajos ,  Pal Benko ,  Laszlo Pallos ,  Lujza Petocz ,  Grasser Katalin ,  Ibolya Kosoczky

发明人： Andras Messmer ,  Sandor Batori ,  Gyorgy Hajos ,  Pal Benko ,  Laszlo Pallos ,  Lujza Petocz ,  Grasser Katalin ,  Ibolya Kosoczky

IPC分类号： C07D253/08 ,  C07D471/04

CPC分类号： C07D471/04

摘要： A one step process for the preparation of compounds having antidepressant activity of the formula I ##STR1## and isomers thereof, wherein R.sub.1, R.sub.2, Z and A.sup.- have the meanings indicated in the claims, which process comprises: heating a compound of the formula II ##STR2## wherein Z, A.sup.-, R.sub.1 and R.sub.2 have the meanings set out in the claims and R.sub.3 stands for hydrogen or C.sub.1-4 alkyl, in the presence of a dehydrating agent to split off a compound of the formula R.sub.3 OH. The invention is also directed to compounds of the formula I, wherein R.sub.2 is halogen and to compositions containing a compound of the formula I which exhibit antidepressant activity.

摘要翻译： 制备具有式I的抗抑郁活性的化合物及其异构体的一步法，其中R1，R2，Z和A具有权利要求中所示的含义，该方法包括：将 式II其中Z，A，R 1和R 2具有权利要求中所述的含义，R 3代表氢或C 1-4烷基，在脱水剂的存在下分离式R 3 OH的化合物 。 本发明还涉及式I化合物，其中R 2是卤素，以及含有表现出抗抑郁活性的式I化合物的组合物。

公开(公告)号：US4324786A

公开(公告)日：1982-04-13

申请号：US143778

申请日：1980-04-25

申请人： Andras Messmer ,  Pal Benko ,  Gyorgy Hajos ,  Lujza Petocz ,  Ibolya Kosoczky ,  Peter Gorog

发明人： Andras Messmer ,  Pal Benko ,  Gyorgy Hajos ,  Lujza Petocz ,  Ibolya Kosoczky ,  Peter Gorog

IPC分类号： A61K31/53 ,  A61K31/535 ,  A61P25/00 ,  A61P25/04 ,  A61P25/20 ,  A61P29/00 ,  C07D221/04 ,  C07D253/10 ,  C07D471/04 ,  C07D471/14

CPC分类号： C07D471/04

摘要： New pyrido[2,3-e]-as-triazine derivatives of the general formula (I), ##STR1## wherein R.sup.1 and R.sup.2 each stand for a C.sub.1-20 alkylcarbonyl, halogenated (C.sub.1-4 alkyl)-carbonyl, C.sub.1-4 alkoxycarbonyl, benzoyl, phenyl-(C.sub.1-4 alkyl)-carbonyl or phenyl-(C.sub.2-4 alkenyl)-carbonyl group or a 5-10-membered mono- or bicyclic nitrogen-containing heterocyclic acid residue (preferably a pyridylcarbonyl group) containing optionally one or more additional nitrogen, oxygen and/or sulfur atoms in the heterocyclic ring, and optionally one or more identical or different substituents selected from the group consisting of halogen, C.sub.1-4 alkoxy, nitro and hydroxy are attached to the aromatic or heterocyclic rings, furthermore one of R.sup.1 and R.sup.2 may also stand for hydrogen atom, orR.sup.1 and R.sup.2 may form, together with the adjacent nitrogen atoms, a pyrazole-2,4 ring having optionally a C.sub.1-6 alkyl substituent in position 3, andR.sup.3 stands for hydrogen, halogen, C.sub.1-4 alkoxy, amino, mono-(C.sub.1-6 alkyl)-amino, di-(C.sub.1-6 alkyl)-amino, hydroxy, alkylated or acylated hydroxy, morpholino, piperazino, N-(C.sub.1-6 alkyl)-piperazino, N-benzylpiperazino or N-pyridylpiperazino group,and pharmaceutically acceptable acid addition salts thereof are prepared by acylating the respective 1,2-unsubstituted 1,2-dihydro-pyrido[2,3-e]-as-triazine derivatives.The new compounds according to the invention act on the central nervous system and exert sedative, analgesic, narcosis potentiating, tetrabenazine antagonizing and antiphlogistic effects. The new compounds according to the invention can be applied to advantage in the therapy.

摘要翻译： 通式（I）的新的吡啶并[2,3-e] -as-三嗪衍生物，其中R 1和R 2各自代表C 1-20烷基羰基，卤代（C 1-4烷基） - 羰基 ，C 1-4烷氧基羰基，苯甲酰基，苯基 - （C 1-4烷基） - 羰基或苯基 - （C 2-4烯基） - 羰基或5-10元单环或双环含氮杂环酸残基（优选 含有任选的一个或多个杂环中的一个或多个另外的氮，氧和/或硫原子，以及任选地一个或多个相同或不同的选自卤素，C 1-4烷氧基，硝基和羟基的取代基被连接到 芳族或杂环，此外，R 1和R 2中的一个也可以代表氢原子，或者R 1和R 2可以与相邻的氮原子一起形成具有任选地C 1-6烷基取代基的吡唑-2,4环的位置 3，R3代表氢，卤素，C1-4烷氧基，氨基，单 - （C1-6烷基） - 氨基，二 - （C1-6烷基） - 氨 羟基，烷基化或酰化羟基，吗啉代，哌嗪子基，N-（C 1-6烷基） - 哌嗪基，N-苄基哌嗪子基或N-吡啶基哌嗪子基及其药学上可接受的酸加成盐， 未取代的1,2-二氢 - 吡啶并[2,3-e] -as-三嗪衍生物。 根据本发明的新化合物作用于中枢神经系统，并施加镇静，止痛，麻醉增强，丁苯那嗪拮抗和消炎作用。 根据本发明的新化合物可以在治疗中有利地应用。

公开(公告)号：US4303660A

公开(公告)日：1981-12-01

申请号：US150349

申请日：1980-05-16

申请人： Edit Berenyi nee Poldermann ,  Eniko Szirt nee Kiszelly ,  Peter Gorog ,  Lujza Petocz ,  Ibolya Kosoczky ,  Agnes Kovacs nee Palotai ,  Gabriella rmos nee Lassu

发明人： Edit Berenyi nee Poldermann ,  Eniko Szirt nee Kiszelly ,  Peter Gorog ,  Lujza Petocz ,  Ibolya Kosoczky ,  Agnes Kovacs nee Palotai ,  Gabriella rmos nee Lassu

IPC分类号： A61K31/4162 ,  A61K31/4745 ,  A61K31/505 ,  A61K31/519 ,  A61P1/00 ,  A61P1/04 ,  A61P25/04 ,  A61P29/00 ,  C07D231/16 ,  C07D487/04

CPC分类号： C07D487/04 ,  C07D231/16

摘要： The invention relates to novel pyrazolo[1,5-c]quinazoline derivatives of the general formula I ##STR1## wherein R represents a hydrogen atom, a C.sub.1-4 alkyl group or an acyl group,R.sub.1 represents a hydrogen atom, a C.sub.1-12 alkyl group, a C.sub.3-8 cycloalkyl group, a C.sub.2-4 alkenyl group, an aralkyl group, wherein the alkyl group has 1 to 4 carbon atoms, a phenylalkenyl group, wherein the alkenyl group has 2 to 4 carbon atoms, furthermore a carboxy group or a phenyl group optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C.sub.1-4 alkoxy, nitro or di(C.sub.1-4 alkyl)amino groups, orR and R.sub.1 may form together a valence bond,R.sub.2 represents a hydrogen atom, a C.sub.1-4 alkyl or a phenyl group, orR.sub.1 and R.sub.2 may form together a C.sub.2-7 alkylene group,R.sub.3 represents a nitro group, an amino group, an alkylamino group, a dialkylamino group, wherein the alkyl groups have 1 to 4 carbon atoms, an alkylideneimino group, wherein the alkylidene group has 1 to 4 carbon atoms, a benzylideneimino group or an acylamino group,and pharmaceutically acceptable acid addition salts thereof.The novel compounds of the general formula I can be employed primarily as analgesic agents.

摘要翻译： 本发明涉及通式I（XIX）的新颖的吡唑并[1,5-c]喹唑啉衍生物，其中R表示氢原子，C1-4烷基或酰基，R1表示氢原子， C1-12烷基，C3-8环烷基，C2-4烯基，其中烷基具有1至4个碳原子的芳烷基，苯基烯基，其中烯基具有2至4个碳原子 此外，羧基或任选被一个或多个选自卤素，羟基，C 1-4烷氧基，硝基或二（C 1-4烷基）氨基的取代基取代的苯基，或R和R 1可以一起形成 价键，R2表示氢原子，C1-4烷基或苯基，或R1和R2可以一起形成C2-7亚烷基，R3表示硝基，氨基，烷基氨基，二烷基氨基 基团，其中烷基具有1至4个碳原子，亚烷基亚氨基，其中亚烷基具有1至4个碳 n原子，亚苄基亚氨基或酰氨基，及其药学上可接受的酸加成盐。 通式I的新化合物可以主要用作止痛剂。

公开(公告)号：US4077999A

公开(公告)日：1978-03-07

申请号：US749399

申请日：1976-12-10

申请人： Zoltan Budai ,  Aranka Lay nee Konya ,  Tibor Mezei ,  Katalin Grasser ,  Eniko Szirt nee Kiszelly ,  Ibolya Kosoczky ,  Lujza E. Petocz

发明人： Zoltan Budai ,  Aranka Lay nee Konya ,  Tibor Mezei ,  Katalin Grasser ,  Eniko Szirt nee Kiszelly ,  Ibolya Kosoczky ,  Lujza E. Petocz

IPC分类号： C07C251/58 ,  C07D295/088 ,  C07C131/02 ,  C07C131/04

CPC分类号： C07D295/088 ,  C07C251/58 ,  C07C2101/08 ,  C07C2101/16 ,  C07C2101/18

摘要： The invention relates to novel oxime ethers of the formula I ##STR1## wherein R stands for a phenyl group which may be substituted by a halogen atom or by one or more C.sub.1 -C.sub.4 alkoxy, hydroxyl, nitro or di(C.sub.1 -C.sub.3 alkyl)amino groups,R.sup.1 and R.sup.2 denote each a hydrogen atom or together a valence bond,A denotes a C.sub.2 -C.sub.4 straight or branched-chain alkylene group,N denotes an integer from 3 to 10, andR.sup.3 and R.sup.4 denote a hydrogen atom or a C.sub.1 -C.sub.4 alkyl group, furthermore to acid addition salts and quaternary ammonium salts thereof. These new compounds are biologically active, and possess primarily local analgesic, spasmolytic, nicotine-lethality inhibiting, tetrabenazine-antagonistic and tetra-cor-spasm inhibiting effects.

摘要翻译： 本发明涉及式I（I）的新型肟醚，其中R代表可被卤素原子取代的苯基或一个或多个C 1 -C 4烷氧基，羟基，硝基或二（C1- C 3烷基）氨基，R 1和R 2各自表示氢原子或价键一起，A表示C 2 -C 4直链或支链亚烷基，N DENOTES AN INTEGER为3〜10，R 3和R 4表示氢 原子或C1-C4烷基，此外还涉及其酸加成盐和季铵盐。 这些新化合物具有生物活性，主要具有局部镇痛，解痉，尼古丁致死抑制，四苯并嗪拮抗和四痉挛抑制作用。

公开(公告)号：US4083978A

公开(公告)日：1978-04-11

申请号：US652806

申请日：1976-01-27

申请人： Zoltan Budai ,  Aranka Lay nee Konya ,  Tibor Mezei ,  Katalin Grasser ,  Eniko Szirt nee Kiszelly ,  Ibolya Kosoczky ,  Lujza E. Petocz

发明人： Zoltan Budai ,  Aranka Lay nee Konya ,  Tibor Mezei ,  Katalin Grasser ,  Eniko Szirt nee Kiszelly ,  Ibolya Kosoczky ,  Lujza E. Petocz

IPC分类号： C07C251/58 ,  C07D295/088 ,  A61K31/495 ,  C07D295/12

CPC分类号： C07D295/088 ,  C07C251/58 ,  C07C2101/08 ,  C07C2101/16 ,  C07C2101/18

摘要： Oxime ethers of the formula ##STR1## wherein R stands for a phenyl group which may be substituted by a halogen chlorine atom or by one to three methoxy groups;R.sup.1 and R.sup.2 denote each a hydrogen atom or together a valence bond;A denotes a C.sub.2 -C.sub.4 straight or branched-chain alkylene group;B is piperazino having a benzyl or C.sub.1-3 alkyl substituent on the nitrogen atom; andn denotes an integer from 3 to 6, have nicotine-lethality inhibiting, tetrabenazine-antagonistic and antiepileptic effects.This invention relates to novel oxime ethers possessing valuable therapeutic effects and their optical isomers and salts.The noval compounds have the general formula I ##STR2## wherein R stands for a phenyl group which may be substituted by a chlorine atom or by one to three methoxy groups;R.sup.1 and R.sup.2 denote each a hydrogen atom or together a valence bond;A denotes a C.sub.2 -C.sub.4 straight or branched-chain alkylene group; is piperazino having a benzyl or C.sub.1-3 alkyl substituent on the nitrogen atom;n denotes an integer from 3 to 6.The scope of the novel oxime ethers of the general formula I comprises obviously also all their possible stereoisomers and the mixtures thereof.The novel compounds of the general formula I can be produced according to the invention in the following ways:A. A ketone of the general formula II ##STR3## wherein R, R.sup.1, R.sup.2 and n have the same meaning as above, whereas Y denotes an oxygen or sulphur atom, is allowed to react with a hydroxylamine derivative of the general formula IIIh.sub.2 n -- o -- a -- b (iii)wherein A and B have the above-specified meaning.Ketones of the general formula II can be produced, e.g., in the way described in J. Am. Chem. Soc. 77, 624 /1955/ or in J. Chem. Soc. 1955, 1126, whereas hydroxylamine derivatives of the general formula III can be prepared, e.g., in the way described in J. Pharm. Sci. 58, 138 /1969/.B. A chlorine compound of the general formula IV ##STR4## wherein R, R.sup.1, R.sup.2 and n have the same meaning as above, is allowed to react with a hydroxylamine derivative of the general formula III, wherein A and B have the above-specified meaning.The compounds of general formula IV can be prepared by reacting 2-(p-chlorobenzal)-cyclohexanone with phosphorus oxychloride.c. An oxime of the general formula V ##STR5## wherein R, R.sup.1, R.sup.2 and n have the same meaning as above, is reacted with a halogen alkylamine derivative of the general formula VIhal -- A -- B (VI)wherein Hal denotes a halogen atom, preferably a chlorine atom, whereas A and B have the above-specified meanings.The oxime of the general formula V can be produced, e.g., in the way described in Org. Synth. Coll. Vol. II, p. 70.d. A compound of the general formula V, wherein R, R.sup.1, R.sup.2 and n have the same meaning as above, is reacted with a dihaloalkane of the general formula VIIIhal -- CH.sub.2 -- A' -- Hal' (VIII)wherein Hal and Hal' denote the same or different halogen atoms, whereas A' denotes a C.sub.1 -C.sub.3 straight or branched-chain alkylene group, and the obtained halogen alkyl ether is aminated.The reaction of the compounds of the general formula II and III (method a/) is carried out preferably in a solvent or a solvent mixture inert for the reaction. Solvents being inert for the reaction are, e.g., alcohols, preferably ethanol, or pyridine, triethyl amine etc. the temperature of the reaction can be varied within very wide limits. Though the reaction takes place according to our experience also at room temperature, the optimum reaction rate can be attained at the boiling point of the reaction mixture.In the reaction of the compounds of the general formula IV and III (method b/) the components can be allowed to react in an inert solent, in the presence of a base. Suitable inert solvents are, e.g., diethyl ether, dibutyl ether, tetrahydrofurane, dioxane, etc., or aromatic or aliphatic hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane, etc., whereas pyridine, triethyl amine, N-methyl morpholine, etc., can be applied as bases. The reaction can be carried out also without any inert solvent, using only the base as a solvent. The temperature of the reaction can be varied within wide limits. The upper limit is determined by the boiling point of the reaction mixture.When the end products are to be produced by a reaction of the compounds specified by the general formulas V and VI (method c/), the reaction is to be carried out in an inert solvent, in the presence of a basic condensing agent. Benzene and its homologues, e.g., toluene, xylene, cumol, etc., can be mentioned as inert solvents. In this case preferably sodium amide or sodium hydride are applied as condensing agents. Obviously the same result can be atained also by other alkali metal amides or hydrides. In that case the use of alcohols, such as ethyl, propyl, butyl alcohols, proved to be the most suitable. When an alkali hydroxide is applied as condensing agent, also water can be used as solvent.When the compounds of the general formula I are produced by reacting compounds of the general formula V with those of the general formula VIII (method d/), the reaction can be carried out in a solvent or a solvent mixture inert for the reaction. Benzene and its homologues, such as toluene, xylene, cumol, etc., can be mentioned as inert solvents. In this case sodium amide or sodium hydride can be used as condensing agents. The same result can be attained on applying an alkali metal as condensing agent but in that case expediently ethanol is used as solvent. The amination of the obtained halogen alkyl ether is carried out under pressure in an autoclave, in the presence of the corresponding amine.The compounds of the general formula I can be converted in a known way into acid addition or quaternary ammonium salts. For the preparation of the acid addition salts physiologically tolerable acids, such as hydrogen halides, sulphuric acid, phosphoric acid, citric acid, tartaric acid, fumaric acid, maleic acid, acetic acid, propionic acid, methane-sulphonic acid, succinic acid, etc., can be preferably applied. In order to prepare quaternary ammonium compounds the compounds of the general formula I are allowed to react with compounds suitable for quaternerization, e.g., with an alkyl halide or methanesulphonic acid ester.The biological activity of the novel compounds according to the invention has been proved by a number of various tests. Of the observed effects the local analgesic, nicotine-lethanlity inhibiting, tetrabenazineantagonistic and antiepileptic effects were the most significant ones.The inhibition of nicotine-lethality was determined on mice by the method of Stone (Stone, C.A. et al.: Arch. Intern. Pharmacodynamie 117, 419 /1958/) in groups of 10 mice each, at oral administration. The results are given in Table I. Table I ______________________________________ Compound LD.sub.50 ED.sub.50 Therapeutic (in Example) mg/kg mg/kg index ______________________________________ 2 1450 43 33.7 10 600 56 10.7 6 650 43 15.1 7 400 11 36.4 15 1900 100 19.0 17 1200 40 30.0 18 1000 70 14.3 Trihexyphenidyl (Artane) 365 40 9.13 ______________________________________ +rb Therapeutic index = LD.sub.50ED.sub.50 The antiepileptic effect was investigated on mice, at oral administration. Maximum electroshock (MES) was provoked by means of corneal electrodes, applying the known method of Swinyard (Swinyard et al.: J. Pharmacol. Exp. Ther. 106, 319-330 /1952/). The effect on tetracor-spasm was examined by the modified method of Banziger and Hane (Banziger, R. and Hane, L.D.: Arch. Int. Pharmacodyn. 167, 245-249 /1967/). The results are given in Table II. Table II ______________________________________ Tetracor- spasm in- MES Thera- hibition Thera- Compound LD.sub.50 ED.sub.50 peutic ED.sub.50 peutic (in Example) mg/kg mg/kg index mg/kg index ______________________________________ 2 1450 150 9.7 50 29.0 1 620 105 5.9 74 8.4 Trimethadion (Ptimal) 2100 490 4.3 400 5.3 ______________________________________ The tetrabenazine-reserpine antagonistic effect was investigated on mice in groups of 10 aminals each, at oral administration. The inhibition or suspension of the effect of the observed maximum dose was recorded, and the ED.sub.50 values were calculated on the basis of the dose vs. effect curves. The results are shown in Table III. Table III ______________________________________ Tetra- benazine Reserpine antago- Thera- antagonism Thera- Compound LD.sub.50 nism,ED.sub.50 peutic ED.sub.50, peutic (in Example) mg/kg mg/kg index mg/kg index ______________________________________ 1 620 7 88.6 over 130 4.8 18 1000 28 36.0 about 250 4 Amitriptylin 225 13 17.3 65 3.5 ______________________________________ The new compounds of formula I and their methods of preparation are further illustrated by the aid of the following non-limiting Examples.EXAMPLE 12-Benzal-1-(N-benzylpiperazinylpropoxyimino)-cyclohexaneA solution of 20.1 g (0.1 moles) of 2-benzalcyclohexanone-oxime in 200 ml anhydrous toluene is dropwise added at 85.degree. C under stirring, to a suspension of 2.4 g (0.1 moles) of sodium hydride in 50 ml of anhydrous toluene. The mixture is kept for two hours at 130.degree. C, then a solution of 27.8 g (0.11 moles) of N-benzylpiperazinylpropyl chloride in 50 ml of anhydrous toluene is added. The mixture is kept for 12 hours at 130.degree. C, then cooled and shaken with a solution of 35 g of tartaric acid in 150 ml water. The aqueous phase is cooled to 0.degree.-5.degree. C and made alkaline to pH 10 with ammonium hydroxide. After extraction with dichloroethane, the solvent is distilled off and the residual crude phase processed to fumarate without any distillation.Yield: 35 g (84.3%).Difumarate: m.p. 196.degree. C.Citrate: m.p. 125.degree.-126.degree. C.Maleinate: m.p. 190.degree. C. (under decomposition).Tartrate: m.p. 198.degree.-200.degree. C.Iodomethylate: m.p. 134.degree.-135.degree. C. (under decomposition).Hydrochloride: m.p. 211.degree.-212.degree. C.Analysis: C.sub.35 H.sub.43 N.sub.3 O.sub.9 Calculated: C, 64.70%; H, 6.67%; N, 6.46%. Found: C, 64.35%; H, 6.70%; N, 6.38%.EXAMPLE 22-Benzal-1-(N-methylpiperazinylpropoxyimino)-cyclohexaneOne proceeds in the way as specified in Example 1, with the difference that, instead of N-benzylpiperazinylpropyl chloride, 19.5 g (0.11 moles) of N-methylpiperazinylpropyl chloride are applied.Yield: 27.4 g (80.5%).Difumarate: m.p. 192.degree. C.Anaylsis: C.sub.29 H.sub.39 N.sub.3 O.sub.9 Calculated: C, 60.71%; H, 6.85%; N, 7.32%. Found: C, 60.58%; H, 7.28%; N, 7.36%.EXAMPLE 31-(N-Methylpiperazinylpropoxyimino)-2-(o-methoxybenzal)-cyclohexaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 23.1 g (0.1 moles) of 2-(o-methoxybenzal)-cyclohexanone oxime and 19.5 g (0.11 moles) of N-methylpiperazinylpropyl chloride, on proceeds in the way as specified in Example 1.Yield: 35.2 g (95%).Fumarate: m.p. 189.degree.-191.degree. C.Analysis: C.sub.30 H.sub.41 N.sub.3 O.sub.10. Calculated: C, 59.69%; H, 6.85%; N, 6.96%. Found: C, 59.43%; H, 7.00%; N, 6.92%.EXAMPLE 41-(N-Methylpiperazinylpropoxyimino)-2-(m-methoxybenzal)-cyclohexaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 23.1 g (0.1 moles) of 2-(m-methoxybenzal)-cyclohexanone oxime and 19.5 g (0.11 moles) of N-methylpiperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 31.2 g (84.2%).Fumarate: m.p. 187.degree.-189.degree. C.Analysis: C.sub.30 H.sub.41 N.sub.3 O.sub.10. Calculated: C, 59.69%; H, 6.85%; N, 6.96%. Found: C, 59.45%; H, 7.00%; N, 6.81%.EXAMPLE 51-(N-Methylpiperazinylpropoxyimino)-2-(p-methoxybenzal)-cyclohexaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 23.1 g (0.1 moles) of 2-(p-methoxybenzal)-cyclohexanone oxime and 19.5 g (0.11 moles) of N-methylpipeazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 30.5 g (82.5%).Fumarate: m.p. 190.degree. C.Analysis: C.sub.30 H.sub.41 N.sub.3 O.sub.10. Calculated: C, 59.69%; H, 6.85%; N, 6.96%. Found: C, 59.54%; H, 6.65%; N, 6.92%.EXAMPLE 61-(N-benzylpiperazinylpropoxyimino)-2-(m-methoxybenzal)-cyclohexaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 23.1 g (0.1 moles) of 2-(m-methoxybenzal)-cyclohexanone oxime and 27.8 g (0.11 moles) of N-benzylpiperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 21.3 g (95.5%).Difumarate: m.p. 195.degree.-197.degree. C.Analysis: C.sub.36 H.sub.45 N.sub.3 O.sub.10 Calculated: C, 63.61%; H, 6.67%; N, 6.18%. Found: C, 63.90%; H, 6.78%; N, 6.12%.EXAMPLE 71-[2'-Methyl-3'-(4"-methylpiperazinylpropoxyimino)]-2-(p-methoxybenzal)-cyclohexaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 23.1 g (0.1 moles) of 2-(p-methoxybenzal)-cyclohexanone oxime and 21.0 g (0.11 moles) of N-methylpiperazinylisobutyl chloride, one proceeds in the way as specified in Example 1.Yield: 32.5 g (84.4%).Difumarate: m.p. 186.degree.-190.degree. C.Analysis: C.sub.31 H.sub.43 N.sub.3 O.sub.10 Calculated: C, 60.28%; H, 7.01%; N, 6.81%. Found: C, 59.92%; H, 7.25%; N, 6.74%.EXAMPLE 81-(N-Methyliperazinylpropoxyimino)-2-(3',4'-dimethoxybenzal)-cyclohexaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 26.1 g (0.1 moles) of 2-(3',4'-dimethoxybenzal)-cyclohexanone oxime and 19.5 g (0.11 moles) of N-methylpiperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 34.1 g (85%).Difumarate: m.p. 186.degree.-188.degree. C.Analysis: C.sub.31 H.sub.43 N.sub.3 O.sub.11 Calculated: C, 58.76%; H, 6.84%; N, 6.63%. Found: C, 58.58%; H, 6.64%, N, 6.61%.EXAMPLE 91-(N-Methylpiperazinylpropoxyimino)-2-(3',4',5'-trimethoxybenzal)-cyclohexaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 29.1 g (0.1 moles) of 2-(3',4',5'-trimethoxybenzal)-cyclohexanone oxime and 19.5 g (0.11 moles) of N-methylpiperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 39.0 g (90.5%).Difumarate: m.p. 185.degree.-186.degree. C.Cyclamate: m.p. 166.degree.-167.degree. C.Analysis: C.sub.32 H.sub.45 N.sub.3 O.sub.12 Calculated: C, 57.92%; H, 6.83%; N, 6.33%. Found: C, 58.24%; H, 7.00%; N, 6.30%.EXAMPLE 101-N-Benzylpiperazinylpropoxyimino)-2-(3',4',5'-trimethoxybenzal)-cyclohexanOn starting from 2.4 g (0.1 moles) of sodium hydride, 29.1 g (0.1 moles) of 2-(3',4',5'-trimethoxybenzal)-cyclohexanone oxime and 27.8 g (0.11 moles) of N-benzylpiperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 46.5 g (92%).Difumarate: m.p. 188.degree.-189.degree. C.Analysis: C.sub.38 H.sub.49 N.sub.3 O.sub.12 Calculated: C, 61.6%; H, 6.7%; N, 5.7%. Found: C, 61.5%; H, 6.9%; N, 5.63%.EXAMPLE 112-Benzal-1-[2'-methyl-3'-(4"-methylpiperazinyl)-propoxyimino]-cyclohexaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 20.1 g (0.1 moles) of 2-benzalcyclohexanone oxime and 20.76 g (0.11 moles) of 2-methyl-3-(4'-methylpiperazinyl)-propyl chloride, one proceeds in the way specified in Example 1.Yield: 29.5 g (83%) of a pale yellow oil.Difumarate: m.p. 190.degree.-191.degree. C.Analysis: C.sub.30 H.sub.41 N.sub.3 O.sub.9 Calculated: C, 61.31%; H, 7.03%; N, 7.15%. Found: C, 61.15%; H, 7.19%; N, 7.28%.EXAMPLE 122-(m-Chlorobenzal)-1-[3'-(4"-methylpiperazinyl)-propoxyimino]-cyclohexaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 23.5 g (0.1 moles) of 2-(m-chlorobenzal)-cyclohexanone oxime and 19.5 g (0.11 moles) of N-methylpiperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 26.8 g (71.4%).Difumarate: m.p. 194.degree.-196.degree. C.Analysis: C.sub.29 H.sub.38 ClN.sub.3 O.sub.9 Calculated: C, 57.25%; H, 6.3%; Cl, 5.84 %; N, 6.4%. Found: C, 57.10%; H, 6.2%; Cl, 5.73%; N, 6.29%.EXAMPLE 132-(p-Chlorobenzyl)-1-[3'-(4"-methylpiperazinyl)-propoxyimino]-cyclohexaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 23.74 g (0.1 moles) of 2-(p-chlorobenzyl)-cyclohexanone oxime and 19.5 g (0.11 moles) of N-methyl-piperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 33.8 g (89.5%).Difumarate: m.p. 194.degree.-195.degree. C.Analysis: C.sub.29 H.sub.40 ClN.sub.3 O.sub.9 Calculated: C, 57.09%; H, 6.60%; Cl, 5.31%; N, 6.89%. Found: C, 57.13%; H, 6.82%; Cl, 5.77%; N, 6.84%.EXAMPLE 142-Benzal-1-[3'-(4"-methylpiperazinyl)-propoxyimino]-cycloheptaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 21.5 g (0.1 moles) of 2benzalcycloheptanone oxime and 19.5 g (0.11 moles) of N-methylpiperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 26.5 g (72.5%).Difumarate: m.p. 196.degree.-197.degree. C (under decomposition).Analysis: C.sub.30 H.sub.41 N.sub.3 O.sub.9 Calculated: C, 61.31%; H, 7.03%; N, 7.15. Found: C, 61.20%; H, 6.94%; N, 7.10%.EXAMPLE 152-Benzal-1-[3'-(4"-methylpiperazinyl)-propoxyimino]-cyclopentaneOn starting from 2.4 g (0.1 moles) of sodium hydride, 18.7 g (0.1 moles) of 2-benzalcyclopentanone oxime and 19.5 g (0.11 moles) of N-methylpiperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 31.3 g (95.8%).Difumarate: m.p. 205.degree.-206.degree. C (under decomposition).Analysis: C.sub.28 H.sub.37 N.sub.3 O.sub.9 Calculated: C, 60.09%; H, 6.66%; N, 7.51%. Found: C, 59.83%; H, 6.50%, N, 7.53%.EXAMPLE 162-Benzal-1-[2'-methyl-3'-(4"-methylpiperazinyl)-propoxyimino]-cyclohexaneThe solution of 20.1 g (0.1 moles) of 2-benzalcyclohexanone oxime in 200 ml of anhydrous toluene is dropwise added at 85.degree. C, under continuous stirring, to the suspension of 2.4 g (0.1 moles) of sodium hydride in 50 ml of anhydrous toluene. After boiling the reaction mixture for 2 hours, 18.86 g (0.11 moles) of 1-bromo-3-chloro-2-methylpropane are added, and the reaction mixture is boiled for a few hours. After cooling the mixture to 80.degree. C, a solution of 11 g (0.11 moles) of N-methylpiperazine in 20 ml of anhydrous toluene is dropwise added and the reaction mixture is kept for further 6 hours at this temperature. After cooling and washing with water, a solution of 22 g of fumaric acid in 220 ml of anhydrous ethanol is poured to the toluene solution, the mixture is cooled, and the precipitated crystals are filtered off. Yield in difumarate: 48 g (81.7%); m.p. 190.degree.-191.degree. C. The produce is identical with that described in Example 11.EXAMPLE 171-(N-Methylpiperazinylpropoxyimino)-2-benzal-cyclooctane difumarateOn starting from 2.4 g (0.1 moles) of sodium hydride, 22.9 g (0.1 moles) of 2-benzalcyclooctanone oxime and 19.5 g (0.11 moles) of N-methylpiperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 33.8 g (95%).Fumarate: m.p. 206.degree.-207.degree. C.Analysis: C.sub.31 H.sub.43 N.sub.3 O.sub.9 Calculated: C, 61.88%; H, 7.20%; N, 6.98%. Found: C, 61.38%; H, 7.05%; N, 6.92%.EXAMPLE 182-Benzal-1-[3'-(4"-benzylpiperazinyl)propoxyimino]-cyclopentane difumarateOn starting from 2.4 g (0.1 moles) of sodium hydride, 18.7 g (0.1 moles) of 2-benzalcyclopentanone oxime and 27.8 g (0.11 moles) of N-benzylpiperazinylpropyl chloride, one proceeds in the way as specified in Example 1.Yield: 37.4 g (94%).Difumarate: m.p. 210.degree.-211.degree. C.Analysis: C.sub.34 H.sub.41 N.sub.3 O.sub.9 Calculated: C, 64.22%; H, 6.50%; N, 6.61%. Found: C, 64.12%, H, 6.61%, N, 6.60%.

摘要翻译： 式（Ⅺ）的肟醚，其中R代表可被卤素氯原子取代的苯基或一至三个甲氧基; R1和R2各自表示氢原子或价键一起; A表示C2-C4直链或支链亚烷基; B是在氮原子上具有苄基或C1-3烷基取代基的哌嗪基; 和N DENOTES IN INTEGER从3到6，具有非口服抑制作用，TETRABENAZINE-ANTAGONISTIC和抗体效应。

公开(公告)号：US4342766A

公开(公告)日：1982-08-03

申请号：US254763

申请日：1981-04-16

申请人： Edit Berenyi nee Poldermann ,  Peter Gorog ,  Katalin Grasser ,  Ibolya Kosoczky ,  Agnes Koracs nee Palotay ,  Lujza Petocz

发明人： Edit Berenyi nee Poldermann ,  Peter Gorog ,  Katalin Grasser ,  Ibolya Kosoczky ,  Agnes Koracs nee Palotay ,  Lujza Petocz

IPC分类号： A61K31/4745 ,  A61K31/53 ,  A61P23/00 ,  A61P25/04 ,  A61P25/08 ,  A61P25/20 ,  A61P29/00 ,  C07D471/04 ,  A61K31/395

CPC分类号： C07D471/04

摘要： New compounds are disclosed of the formulae ##STR1## or pharmaceutically effective salts thereof, wherein R is hydrogen, C.sub.1-12 alkyl, or R is phenyl or phenyl-C.sub.1 to C.sub.4 alkyl wherein the phenyl can be substituted with 1 to 3 halogen, C.sub.1 to C.sub.4 alkyl, or C.sub.1 to C.sub.4 alkoxy substituents; andX.sub.1, X.sub.2 and X.sub.3 are hydrogen, C.sub.1 to C.sub.6 alkanoyl, or C.sub.1 to C.sub.6 haloalkanoyl; and where X.sub.1 is hydrogen, X.sub.2 and X.sub.3 are not simultaneously hydrogen. The compounds possess antiphlogistic, analgesic, anticonvulsive, or tranquilizing properties.

摘要翻译： 公开了新的化合物或其药学有效盐，其中R是氢，C 1-12烷基或R是苯基或苯基-C 1至C 4烷基，其中苯基可被1至3个卤素取代，C 1 至C 4烷基或C 1至C 4烷氧基取代基; 且X 1，X 2和X 3为氢，C 1至C 6烷酰基或C 1至C 6卤代烷酰基; 并且其中X1为氢，X2和X3不同时为氢。 该化合物具有消炎，镇痛，抗惊厥或镇静作用。